Tiagabine
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Tiagabine
Tiagabine: Known uses and market status in Australia
Summary
The TxGNN model produced candidates for Tiagabine, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The sections below show how the model’s candidates relate to known uses.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 0 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13892E | Gabitril | Tablet 5 mg (as hydrochloride) | Valid |
Safety Considerations
- Knowledge-graph contraindication signals (from the TxGNN knowledge graph, not product label text): anxiety disorder, neurotic disorder, dysthymic disorder, liver disease, gallbladder disease.
- Drug interactions: 97 interactions were identified. Moderate-level interactions include aprepitant, morphine (including liposomal), opium, dronabinol, nabilone and metoclopramide. Other interactions (e.g. pantoprazole, omeprazole, metformin, simvastatin) are of unknown severity.
- Seizure-related safety signal: the literature reports tiagabine-associated non-convulsive status epilepticus, particularly at higher or rapidly increased doses. This is relevant to any use in reflex epilepsy syndromes.
- Visual effects: antiepileptic drugs can cause visual disturbances, and visual field effects are discussed for GABAergic agents. This warrants attention when considering a visual-trigger indication.
Warnings and contraindications from the TGA-approved Product Information (PI) were not available. Please refer to the PI for full safety information.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.